Your browser is no longer supported. Please, upgrade your browser.
Settings
XERS Xeris Pharmaceuticals, Inc. daily Stock Chart
XERS [NASD]
Xeris Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-4.04 Insider Own2.50% Shs Outstand26.89M Perf Week-6.73%
Market Cap290.67M Forward P/E- EPS next Y-2.98 Insider Trans- Shs Float26.41M Perf Month-11.54%
Income-94.80M PEG- EPS next Q-1.23 Inst Own74.90% Short Float6.52% Perf Quarter-4.93%
Sales2.00M P/S145.34 EPS this Y-114.60% Inst Trans10.47% Short Ratio8.75 Perf Half Y6.82%
Book/sh2.78 P/B3.89 EPS next Y36.20% ROA-68.70% Target Price21.25 Perf Year-57.77%
Cash/sh4.63 P/C2.33 EPS next 5Y- ROE-107.70% 52W Range6.85 - 27.98 Perf YTD-36.41%
Dividend- P/FCF- EPS past 5Y- ROI-55.30% 52W High-61.37% Beta-
Dividend %- Quick Ratio6.00 Sales past 5Y- Gross Margin98.80% 52W Low57.81% ATR0.83
Employees113 Current Ratio6.00 Sales Q/Q-62.50% Oper. Margin- RSI (14)45.74 Volatility7.55% 7.98%
OptionableYes Debt/Eq0.43 EPS Q/Q-103.70% Profit Margin- Rel Volume0.66 Prev Close11.45
ShortableYes LT Debt/Eq0.39 Earnings- Payout- Avg Volume196.84K Price10.81
Recom- SMA20-4.35% SMA50-5.44% SMA200-18.51% Volume129,577 Change-5.59%
Jul-16-18Initiated RBC Capital Mkts Outperform $24
Jul-16-18Initiated Leerink Partners Outperform $24
Jul-16-18Initiated Jefferies Buy $23
Aug-06-19 07:45PM  Xeris Pharmaceuticals, Inc. (XERS) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:05PM  Xeris Pharmaceuticals Announces Second Quarter 2019 Financial Results and Highlights GlobeNewswire
Aug-05-19 10:31AM  Xeris Pharmaceuticals, Inc. (XERS) May Report Negative Earnings: Know the Trend Ahead of Q2 Release Zacks -5.58%
Aug-02-19 04:05PM  Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) GlobeNewswire -6.20%
Jul-18-19 01:09PM  Did Changing Sentiment Drive Xeris Pharmaceuticals's (NASDAQ:XERS) Share Price Down By 38%? Simply Wall St.
Jun-28-19 04:05PM  Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire +6.42%
Jun-27-19 08:00AM  Xeris Pharmaceuticals Doses First Patient in Phase 2 Trial Evaluating Its Developmental Ready-to-use Glucagon in Patients at Risk From Hypoglycemia Following Bariatric Surgery Business Wire
Jun-17-19 08:00AM  Xeris Pharmaceuticals Announces Additional Positive Outcomes from a Global Phase 3 Clinical Trial of Its Investigational Ready-to-Use Glucagon Business Wire +8.43%
May-25-19 09:03AM  Can We See Significant Institutional Ownership On The Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) Share Register? Simply Wall St.
May-09-19 04:05PM  Xeris Pharmaceuticals Announces First Quarter 2019 Financial Results and Highlights Its Pipeline GlobeNewswire +5.35%
May-01-19 08:00AM  Xeris Pharmaceuticals Announces Results From a Phase 1 Study of Its Novel Formulation of Diazepam GlobeNewswire
Apr-26-19 04:01PM  Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Mar-29-19 04:05PM  Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) GlobeNewswire
Mar-25-19 08:45AM  Xeris Pharmaceuticals Presents New Clinical and Economic Impact Data on Its Developmental Ready-to-Use Glucagon Business Wire
Mar-14-19 04:15PM  Xeris Pharmaceuticals Doses First Patient in Phase 2 Trial Evaluating Its Ready-to-Use Glucagon to Address Exercise-Induced Hypoglycemia Business Wire
Mar-12-19 03:36PM  How Many Insiders Bought Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) Shares? Simply Wall St.
Mar-06-19 04:10PM  Xeris Pharmaceuticals Announces Fourth Quarter and Full Year 2018 Financial Results and Highlights Pipeline Progress GlobeNewswire
Mar-01-19 04:15PM  Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Feb-20-19 07:30AM  Xeris Pharmaceuticals to Participate at SVB Leerink Global Healthcare Conference GlobeNewswire
Feb-13-19 07:26PM  Xeris Pharmaceuticals Announces Pricing of Public Offering of Shares of Common Stock GlobeNewswire -8.67%
Feb-12-19 04:33PM  Why Molson Coors Brewing, Xeris Pharmaceuticals, and Varonis Systems Slumped Today Motley Fool -21.50%
08:04AM  The Daily Biotech Pulse: NASH Disappointment For Gilead, Xeris To Offer Shares Benzinga
Feb-11-19 04:05PM  Xeris Pharmaceuticals Announces Proposed Public Offering of Shares of Common Stock GlobeNewswire
Dec-20-18 08:30AM  European Medicines Agency Grants Orphan Drug Designation for Xeris Investigational Ready-to-Use Glucagon for the Treatment of Non-Insulinoma Pancreatogenous Hypoglycaemia Syndrome (NIPHS) Business Wire -11.96%
Nov-07-18 08:00AM  Xeris Pharmaceuticals Announces Third Quarter 2018 Financial Results and Highlights Pipeline Progress GlobeNewswire
Oct-23-18 08:30AM  Xeris Pharmaceuticals Announces FDA Acceptance for Review of NDA for Its Ready-to-Use Glucagon Rescue Pen Business Wire
Aug-17-18 08:30AM  Xeris Pharmaceuticals and OHSU Conducting Artificial Pancreas Clinical Trial Using Xeris Novel Ready-to-Use Liquid Glucagon Business Wire
Aug-13-18 08:00AM  Xeris Pharmaceuticals Announces Second Quarter 2018 Financial Results and Business Highlights GlobeNewswire
Jul-31-18 07:00AM  Xeris Pharmaceuticals to Present at Two Upcoming Investor Conferences GlobeNewswire
Jul-30-18 07:00AM  Xeris Pharmaceuticals Announces New Board Members and New Executive to Management Team GlobeNewswire
Jun-26-18 04:15PM  Xeris Pharmaceuticals Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
Jun-25-18 04:15PM  Xeris Pharmaceuticals Announces Positive Phase 3 Clinical Trial Data on Its Investigational Ready-to-Use Glucagon Rescue Pen Business Wire
Jun-21-18 11:41AM  [$$] Banner Day for Biotech as Five Drug Developers Go Public The Wall Street Journal
Jun-20-18 06:31PM  Xeris Pharmaceuticals Announces Pricing of Initial Public Offering of Common Stock GlobeNewswire
Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps. The company's lead product candidate is Gvoke HypoPen, which has completed Phase III clinical trials for the treatment of severe hypoglycemia, a potentially life-threatening condition in people with diabetes. Its product candidates also comprise ready-to-use glucagon that is in Phase II clinical trials for the treatment of congenital hyperinsulinism, post-bariatric hypoglycemia, exercise-induced hypoglycemia in diabetes, and hypoglycemia-associated autonomic failure, as well as for treating hypoglycemia associated with intermittent and chronic conditions, and bi-hormonal artificial pancreas closed-loop systems. In addition, it develops continuous subcutaneous glucagon infusion system of ready-to-use glucagon; ready-to-use diazepam formulation, which is in Phase I clinical trial for the treatment of acute repetitive seizures in patients with epilepsy; and Pramlintide-Insulin co-formulation that is in pre-clinical stage for treating type 1 and 2 diabetes. Xeris Pharmaceuticals, Inc. serves patients, caregivers, and health practitioners. The company was founded in 2005 and is based in Chicago, Illinois.